Next |
home / stock / avir / avir message board
Subject | By | Source | When |
---|---|---|---|
Tang Capital makes unsolicited $AVIR buyout offer@$5.75/sh +CVRa 55% premium to | DewDiligence | investorshub | 05/22/2023 3:14:19 PM |
Tang Capital makes unsolicited $AVIR buyout offer@$5.75/sh +CVRa 55% premium to Fridays close: | DewDiligence | investorshub | 05/22/2023 2:54:56 PM |
Volume | Awl416 | investorshub | 05/22/2023 1:04:50 PM |
Price now last up | Docstemcell2020 | investorshub | 05/21/2023 10:32:28 AM |
Have a look at this | DewDiligence | investorshub | 05/19/2023 7:33:19 PM |
$AVIR MomentumIts now last up | crudeoil24 | investorshub | 05/17/2023 1:45:16 PM |
When is this gonna take off? | DewDiligence | investorshub | 05/17/2023 5:19:07 AM |
MomentumIts gaining | Mikey | investorshub | 05/14/2023 9:06:53 PM |
must see | Planopenny | investorshub | 05/14/2023 1:48:27 PM |
$AVIR what does this mean? | dealerschool2006 | investorshub | 05/12/2023 5:30:03 AM |
$AVIR 1Q23 CC transcript: | DewDiligence | investorshub | 05/09/2023 9:58:24 PM |
$AVIR 1Q23 results: | DewDiligence | investorshub | 05/09/2023 9:58:00 PM |
So $AVIR beat its earnings, and now it | V63 | investorshub | 05/08/2023 8:48:47 PM |
$AVIR Price gaining last up | crudeoil24 | investorshub | 05/06/2023 8:50:29 PM |
Found an interesting article | DewDiligence | investorshub | 05/05/2023 12:32:57 PM |
$AVIR The trading last up | DewDiligence | investorshub | 05/03/2023 6:53:09 PM |
$AVIR Time for a bounce? | DewDiligence | investorshub | 05/02/2023 11:05:17 AM |
$AVIR When is this gonna take off? | rosemountbomber | investorshub | 04/30/2023 4:35:03 AM |
The now | tulla236a | investorshub | 04/29/2023 6:04:29 PM |
$AVIR short squeeze all day | crudeoil24 | investorshub | 04/27/2023 12:06:26 PM |
News, Short Squeeze, Breakout and More Instantly...
Atea Pharmaceuticals Inc. Company Name:
AVIR Stock Symbol:
NASDAQ Market:
BOSTON, April 29, 2024 (GLOBE NEWSWIRE) -- Atea Pharmaceuticals, Inc. (NASDAQ:AVIR) (Atea), a clinical-stage biopharmaceutical company engaged i...
BOSTON, April 29, 2024 (GLOBE NEWSWIRE) -- Atea Pharmaceuticals, Inc. (Nasdaq: AVIR) (Atea), a clinical-stage biopharmaceutical company engaged in the discovery and development of oral antiviral therapeutics for serious viral diseases, today announced the presentation of Phase 1 data highlighting...
Enrollment Reached Over 2,200 High-Risk Patients in Bemnifosbuvir Monotherapy Cohort Results from SUNRISE-3 Expected in 2H’24 BOSTON, March 27, 2024 (GLOBE NEWSWIRE) -- Atea Pharmaceuticals, Inc. (Nasdaq: AVIR) (Atea), a clinical-stage biopharmaceutical company engaged in the...